In Vitro Probiotic Properties of Bifidobacterium animalis subsp. lactis SF and Its Alleviating Effect on Non-Alcoholic Fatty Liver Disease

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease with many influencing factors. With the increasing role of the gut–liver axis in various liver diseases, research on the prevention and treatment of NAFLD with probiotics is increasing. In the present study, a Bifidobacterium animalis subsp. strain, B. lactis SF, was isolated from the feces of healthy infants and characterized by sequencing of the 16S rDNA. A systematic probiotic evaluation was carried out, and a diet-induced mouse model was constructed to study the effect and mechanism of B. lactis SF on diet-induced NAFLD. Results show that B. lactis SF has excellent gastrointestinal fluid tolerance and intestinal colonization, and strong antibacterial and antioxidant capabilities. In vivo, B. lactis SF modulated intestinal flora, restored the intestinal barrier, and inhibited LPS entrance into the portal circulation, which subsequently inhibited the TLR4/NF-κB and modulated the PI3K-Akt/AMPK signaling pathway, attenuated the inflammatory response, and reduced lipid accumulation. In addition, B. lactis SF attenuated oxidative stress and further alleviated autophagy, resulting in an ameliorative effect on NAFLD. Therefore, our study provides a new dietary method for the treatment of NAFLD.

The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota

“…Collectively, the articles reviewed in this study all aligned in the same direction: Bifidobacterium acts beneficially as a probiotic in NAFLD, ALD, and Cirrhosis. It does so by restoring the intestinal microbiota balance, reducing inflammation and oxidative [23,[28][29][30], whereas (B) represents the same for animal studies [19][20][21][22][24][25][26][27]. The letter "D" denotes the domains present in the checklists.…”

“…These data were accompanied by improvements in biochemical parameters such as the antioxidant molecules catalase (CAT), glutathione (GSH), superoxide dismutase (SOD), and malondialdehyde (MDA). Therefore, there was a significant improvement in immune balance, intestinal mucosal health, and hepatic metabolism [26][27][28][29][30].…”

Advances and optimization strategies in bacteriophage therapy for treating inflammatory bowel disease

“…The results demonstrated that Lactobacillus SF could restore gut microbiota balance by increasing the relative abundance of bacteria capable of occupying the same ecological niche as pathogenic bacteria, thereby reducing the survival space for pathogens. This indicates that Lactobacillus SF exhibits excellent resistance to gastric fluids, colonization in the intestine, and strong antibacterial and antioxidant capabilities ( 84 ).…”

Mechanisms and Therapeutic Strategies for MAFLD Targeting TLR4 Signaling Pathways

“…Probiotic supplementation may facilitate gut microbiota homeostasis, enhance intestinal barrier integrity, and attenuate pro-inflammatory cytokine production in MAFLD patients. Several specific strains of probiotics, such as Lactobacillus kefiranofaciens ZW3 [ 106 ], Lactobacillus rhamnosus and Pediococcus acidilactici [ 107 ], Bifidobacterium adolescentis [ 108 , 109 ], and Grifola frondosa [ 110 ] are considered to treat MAFLD by inhibiting the TLR4/MyD88/JNK/NF-κB/TRAF6/NLRP3 pathway, reducing the release of inflammatory factors, improving IR, and restoring lipid metabolism. Probiotic derivatives may also exert anti-MAFLD effects.…”